Therapeutic strategies being developed for MJD focus on targeting ATXN3 using small molecules or gene therapy to manipulate synthesis, concentration, conformation, and/or the location of this protein (reviewed in [7]). Here, ATXN3 is linked to Spinocerebellar ataxia type 3.